Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Orion Oyj Class B represents the publicly traded Class B shares of Orion Oyj, a globally operating Finnish pharmaceutical company founded in 1917 and headquartered in Espoo, Finland. The company develops, manufactures, and markets human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients, with a primary focus on treatments for central nervous system disorders, oncology, respiratory diseases, prostate cancer, Parkinson's disease, asthma, chronic obstructive pulmonary disease, and inflammatory pain. Notable products include Nubeqa for prostate cancer, Stalevo and Comtess for Parkinson's, Easyhaler inhalers for respiratory conditions, and veterinary drugs like Domosedan and Antisedan. Orion Oyj serves specialists, general practitioners, veterinarians, pharmacies, hospitals, and laboratories, with its core market in Finland and additional presence across Europe, North America, and other regions. Employing around 3,989 people, it operates in the pharmaceuticals and biotech sector, contributing to healthcare innovation through proprietary developments, contract manufacturing, and strategic collaborations for antibody therapeutics.
€72.23
+€1.20 (+1.69%)
EOD Jul 2, 2026
Margins and capital returns are both well above average: 33.29% operating margin, ROIC at 34.31%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 22.5% YoY with margins expanding 6.4pp.
Even for strong businesses, today's 19x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
19.2x earnings, 57.7x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1.95B
▲ +22.5% YoY
Net Income (TTM)
€529M
▲ +51.7% YoY
Op. Margin
34.10%
▲ +6.4pp YoY
ROIC
34.31%
▲ +7.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€176M
▲ +6.2% YoY
Op. Cash Flow (TTM)
€303M
▼ -1.5% YoY
Net Debt
€144M
Cash & Equiv.
€161M
3Y CAGR: +12.1%
3Y CAGR: -15.3%
Continue Research
At a P/E of 19.2 and a price-to-free-cash-flow of 57.7, Orion Oyj Class B (ORNBV.XHEL) trades above a two-stage DCF intrinsic value of about €26.97 per share, so at €72.23 the stock looks overvalued (62.7% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Orion Oyj Class B scores 61/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 2.3%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €26.97 per share for ORNBV.XHEL, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €20.23. At today's €72.23, that puts the stock about 62.7% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Orion Oyj Class B scores 61 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 34.1% operating margin and a 34.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Orion Oyj Class B pays a regular dividend of about €1.64 per share per year (typically in quarterly installments), a yield of roughly 2.3% at the current price. That is a payout ratio of about 43.7% of earnings, so the dividend is well covered. Orion Oyj Class B has grown the dividend at roughly 2.3% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For ORNBV.XHEL's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. ORNBV.XHEL currently trades above its estimated intrinsic value and scores 61/100 on quality (solid). It also yields about 2.3%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.